Hyoscine Butylbromide – Risk of adverse effects in patients with underlying cardiac disease

Hyoscine Butylbromide – Risk of adverse effects in patients with underlying cardiac disease

lngelheim Pharmaceuticals (Pty) Ltd and Sanofi-Aventis South Africa (Pty) Ltd in collaboration with SAHPRA wish to inform you of the following safety information update regarding the use of hyoscine butylbromide injection as contained in BUSCOPAN 20 mg/1 ml ampoules and BUSCOPAN COMPOSITUM 20 mg/2,5 g injection.

2019 Apr

Download latest version
File Type: pdf
Category: Communication To Health Care Professionals
Unit: pharmacovigilance